Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.

ABSTRACT:

Background

Sunitinib is an oral multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors, as well as of other receptor types. We have performed a feasibility study to investigate the safety of sunitinib in combination with pemetrexed for treatment of advanced refractory solid tumors.

Methods

Sunitinib was administered once daily on a continuous daily dosing (CDD) schedule (37.5 mg/day) or a 2-weeks-on, 1-week-off treatment schedule (50 mg/day, Schedule 2/1) in combination with pemetrexed at 500 mg/m(2) on day 1 of repeated 21-day cycles.

Results

Twelve patients were enrolled in the study: six on the CDD schedule and six on Schedule 2/1. None of the treated patients experienced a dose-limiting toxicity.

SUBMITTER: Okamoto I 

PROVIDER: S-EPMC3277823 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature